Evidence map›Paper›PMID 37029329›Full record

ArticleBreast cancer research and treatment2023

Association of baseline ROR1 and ROR2 gene expression with clinical outcomes in the I-SPY2 neoadjuvant breast cancer trial.

Barbara A Parker, Rebecca A Shatsky, Richard B Schwab, Anne M Wallace, I-SPY 2 Consortium, Denise M Wolf, Gillian L Hirst, Lamorna Brown-Swigart, Laura J Esserman, Laura J van 't Veer and 3 more

Registry-linked trialOpen access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Breast cancer research and treatment, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01042379 (I-SPY Trial), which is not on this map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01042379 phase2recruitingnot on this map

I-SPY Trial (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis 2)

TypeinterventionalSponsorQuantumLeap Healthcare CollaborativeRan2010 to 2031Enrolled5,000ConditionsBreast Neoplasms, Breast Cancer, Breast Tumors, AngiosarcomaArmsStandard Therapy, AMG 386 with or without Trastuzumab, AMG 479 (Ganitumab) plus Metformin, MK-2206 with or without Trastuzumab, AMG 386 and Trastuzumab
3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Barbara A ParkerDepartment of Medicine and Moores Cancer Center, University of California San Diego, La Jolla, CA, 92093, USA. baparker@health.ucsd.edu.ORCID http://orcid.org/0000-0003-0499-1289
Rebecca A ShatskyDepartment of Medicine and Moores Cancer Center, University of California San Diego, La Jolla, CA, 92093, USA.
Richard B SchwabDepartment of Medicine and Moores Cancer Center, University of California San Diego, La Jolla, CA, 92093, USA.
Anne M WallaceDepartment of Surgery and Moores Cancer Center, University of California San Diego, La Jolla, CA, USA.
I-SPY 2 Consortium
Denise M WolfDepartment of Laboratory Medicine, University of California San Francisco, San Francisco, CA, USA.
Gillian L HirstDepartment of Surgery, University of California San Francisco, San Francisco, CA, USA.
Lamorna Brown-SwigartDepartment of Laboratory Medicine, University of California San Francisco, San Francisco, CA, USA.
Laura J EssermanDepartment of Surgery, University of California San Francisco, San Francisco, CA, USA.
Laura J van 't VeerDepartment of Laboratory Medicine, University of California San Francisco, San Francisco, CA, USA.
Emanuela M GhiaDepartment of Medicine and Moores Cancer Center, University of California San Diego, La Jolla, CA, 92093, USA.ORCID http://orcid.org/0000-0002-6060-6106
Christina YauDepartment of Surgery, University of California San Francisco, San Francisco, CA, USA.
Thomas J KippsDepartment of Medicine and Moores Cancer Center, University of California San Diego, La Jolla, CA, 92093, USA.ORCID http://orcid.org/0000-0002-0064-4549
University of California, San Francisco · USUniversity of California San Diego · USUC San Diego Health System · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeROR1 and ROR2 are Type 1 tyrosine kinase-like orphan receptors for Wnt5a that are associated with breast cancer progression. Experimental agents targeting ROR1 and ROR2 are in clinical trials. This study evaluated whether expression levels of ROR1 or ROR2 correlated with one another or with clinical outcomes.

methodsWe interrogated the clinical significance of high-level gene expression of ROR1 and/or ROR2 in the annotated transcriptome dataset from 989 patients with high-risk early breast cancer enrolled in one of nine completed/graduated/experimental and control arms in the neoadjuvant I-SPY2 clinical trial (NCT01042379).

resultsHigh ROR1 or high ROR2 was associated with breast cancer subtypes. High ROR1 was more prevalent among hormone receptor-negative and human epidermal growth factor receptor 2-negative (HR-HER2-) tumors and high ROR2 was less prevalent in this subtype. Although not associated with pathologic complete response, high ROR1 or high ROR2 each was associated with event-free survival (EFS) in distinct subtypes. High ROR1 associated with a worse EFS in HR + HER2- patients with high post-treatment residual cancer burden (RCB-II/III) (HR 1.41, 95% CI = 1.11-1.80) but not in patients with minimal post-treatment disease (RCB-0/I) (HR 1.85, 95% CI = 0.74-4.61). High ROR2 associated with an increased risk of relapse in patients with HER2 + disease and RCB-0/I (HR 3.46, 95% CI = 1.33-9.020) but not RCB-II/III (HR 1.07, 95% CI = 0.69-1.64).

conclusionHigh ROR1 or high ROR2 distinctly identified subsets of breast cancer patients with adverse outcomes. Further studies are warranted to determine if high ROR1 or high ROR2 may identify high-risk populations for studies of targeted therapies.

Indexed as

Breast NeoplasmsFemaleGene ExpressionHumansNeoadjuvant TherapyNeoplasm Recurrence, LocalReceptor Tyrosine Kinase-like Orphan ReceptorsReceptor Tyrosine Kinase-like Orphan ReceptorsROR1 protein, humanROR2 protein, humanBreast cancerI-SPY2OutcomesROR1ROR2

Identifiers

PMID37029329
PMCPMC10175386
OpenAlexW4362716822

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.